CordenPharma, a global CDMO, has committed to spending more than €900m during the next three years to grow its peptide technology platform.
This strategy will expand the company’s peptide manufacturing capabilities in the US and Europe — with efforts placed in building on existing facilities, as well as constructing novel sites.
Building on the Colorado facility
The US expansion will bring additional peptide capacity to the Colorado site, where the company plans to construct a large-scale manufacturing facility, while also increasing the production capabilities of its existing infrastructure.
The main focus of the site will be in the production of GLP-1 agonist medications, which have seen a sharp increase in demand during the last few years.
Expanding further into Europe
The European segment of the expansion will involve the building of a novel facility, which will boost the company’s peptide manufacturing capacity, allowing it to serve customers from early clinical to late-stage commercial.
The new site will be located in central Europe, and will be fully integrated with CordenPharma’s existing facility network.
When completed, both expansion projects will be linked to CordenPharma’s current network of manufacturing facilities, and will receive technical and regulatory support from dedicated company experts.
President & CEO of CordenPharma Group, Dr Michael Quirmbach commented: “These investments will profoundly strengthen our ability to provide support to innovators for the benefit of patients. In addition, the strong commitment and support of our shareholder Astorg demonstrates their strategic vision for CordenPharma to become the leading CDMO for complex modalities such as Peptides, by offering fully-integrated end-to-end services from APIs to Drug Products (for both Injectable and Oral Peptides).”
